Search Results

There are 4154 results for: content related to: Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

  1. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time

    International Journal of Clinical Practice

    Volume 69, Issue 2, February 2015, Pages: 186–198, S. Parikh, J. Wilding, S. Jabbour and E. Hardy

    Article first published online : 28 NOV 2014, DOI: 10.1111/ijcp.12531

  2. You have free access to this content
    The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

    British Journal of Clinical Pharmacology

    Volume 76, Issue 3, September 2013, Pages: 432–444, Sreeneeranj Kasichayanula, Xiaoni Liu, Melanie Pe Benito, Ming Yao, Marc Pfister, Frank P. LaCreta, William Griffith Humphreys and David W. Boulton

    Article first published online : 20 AUG 2013, DOI: 10.1111/bcp.12056

  3. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 4, April 2011, Pages: 357–365, S. Kasichayanula, M. Chang, M. Hasegawa, X. Liu, N. Yamahira, F. P. LaCreta, Y. Imai and D. W. Boulton

    Article first published online : 23 FEB 2011, DOI: 10.1111/j.1463-1326.2011.01359.x

  4. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 1, January 2015, Pages: 42–51, P.-M. Schumm-Draeger, L. Burgess, L. Korányi, V. Hruba, J. E. Hamer-Maansson and T. W. A. de Bruin

    Article first published online : 16 OCT 2014, DOI: 10.1111/dom.12387

  5. You have full text access to this OnlineOpen article
    Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 9, September 2013, Pages: 853–862, H. J. Lambers Heerspink, D. de Zeeuw, L. Wie, B. Leslie and J. List

    Article first published online : 5 JUN 2013, DOI: 10.1111/dom.12127

  6. You have free access to this content
    Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 5, May 2013, Pages: 392–402, L. H. Chen and P. S. Leung

    Article first published online : 6 FEB 2013, DOI: 10.1111/dom.12064

  7. You have free access to this content
    Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 2, February 2014, Pages: 159–169, J. Bolinder, Ö. Ljunggren, L. Johansson, J. Wilding, A. M. Langkilde, C. D. Sjöström, J. Sugg and S. Parikh

    Article first published online : 29 AUG 2013, DOI: 10.1111/dom.12189

  8. Dapagliflozin: A Novel Sodium-Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 1, January 2012, Pages: 80–94, Niren K. Shah, Wasim E. Deeb, Rushab Choksi and Benjamin J. Epstein

    Article first published online : 4 JAN 2012, DOI: 10.1002/PHAR.1010

  9. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability

    Clinical Pharmacology in Drug Development

    Tjerk W.A. de Bruin, Stots Reele, Jennifer E. Hamer-Maansson, Shamik Parikh and Weifeng Tang

    Article first published online : 20 OCT 2015, DOI: 10.1002/cpdd.220

  10. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

    International Journal of Clinical Practice

    Volume 66, Issue 5, May 2012, Pages: 446–456, R. R. Henry, A. V. Murray, M. H. Marmolejo, D. Hennicken, A. Ptaszynska and J. F. List

    Article first published online : 13 MAR 2012, DOI: 10.1111/j.1742-1241.2012.02911.x

  11. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 7, July 2014, Pages: 628–635, J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H. L. Grossman and M. Cohen

    Article first published online : 19 FEB 2014, DOI: 10.1111/dom.12261

  12. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial

    Diabetic Medicine

    Volume 32, Issue 4, April 2015, Pages: 531–541, C. J. Bailey, E. C. Morales Villegas, V. Woo, W. Tang, A. Ptaszynska and J. F. List

    Article first published online : 22 NOV 2014, DOI: 10.1111/dme.12624

  13. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 11, November 2015, Pages: 1075–1084, S. Matthaei, K. Bowering, K. Rohwedder, J. Sugg, S. Parikh, E. Johnsson and on behalf of the Study 05 Group

    Article first published online : 4 SEP 2015, DOI: 10.1111/dom.12543

  14. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 6, June 2015, Pages: 581–590, S. Del Prato, M. Nauck, S. Durán-Garcia, L. Maffei, K. Rohwedder, A. Theuerkauf and S. Parikh

    Article first published online : 6 APR 2015, DOI: 10.1111/dom.12459

  15. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 11, November 2014, Pages: 1111–1120, M. A. Nauck, S. Del Prato, S. Durán-García, K. Rohwedder, A. M. Langkilde, J. Sugg and S. J. Parikh

    Article first published online : 10 JUL 2014, DOI: 10.1111/dom.12327

  16. You have free access to this content
    Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 2, February 2014, Pages: 124–136, J. P. H. Wilding, V. Woo, K. Rohwedder, J. Sugg, S. Parikh and for the Dapagliflozin 006 Study Group

    Article first published online : 29 AUG 2013, DOI: 10.1111/dom.12187

  17. You have full text access to this OnlineOpen article
    Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 2, February 2015, Pages: 188–197, S. Sha, D. Polidori, K. Farrell, A. Ghosh, J. Natarajan, N. Vaccaro, J. Pinheiro, P. Rothenberg and L. Plum-Mörschel

    Article first published online : 5 JAN 2015, DOI: 10.1111/dom.12418

  18. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 1, January 2011, Pages: 47–54, S. Kasichayanula, X. Liu, W. C. Shyu, W. Zhang, M. Pfister, S. C. Griffen, T. Li, F. P. LaCreta and D. W. Boulton

    Article first published online : 28 NOV 2010, DOI: 10.1111/j.1463-1326.2010.01314.x

  19. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 5, May 2013, Pages: 432–440, K. Kaku, S. Inoue, O. Matsuoka, A. Kiyosue, H. Azuma, N. Hayashi, T. Tokudome, A. M. Langkilde and S. Parikh

    Article first published online : 25 JAN 2013, DOI: 10.1111/dom.12047

  20. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 10, October 2012, Pages: 951–959, C. J. Bailey, N. Iqbal, C. T'joen and J. F. List

    Article first published online : 24 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01659.x